The conclusion of the reconstruction entails that the Company returns to ordinary operations and continues the implementation of the measures set out in the reconstruction plan. The dismissal decision will be made available on the Company’s website:
https://www.peptonicmedical.se/investerare/foretagsrekonstruktion-2025/

For further information, please contact:

Anna Linton, CEO, Peptonic Medical AB                                                                                                                           Email: anna.linton@peptonicmedical.se                                                                                                                      

About Peptonic Medical AB                                                                                                          

Peptonic Medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.